{
  "docId": "019de073-f0bf-7547-8ad6-12100ed22e83",
  "docSlug": "a88a01f7711a3a01e2c4b1dc80e80f39",
  "documentTitle": "BenevolentAI | Investor Conference Presentation Deck | 17 slides",
  "authorId": "benevolentai",
  "authorName": "BenevolentAI",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 17,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide includes explicit caveats regarding the small sample size and short duration of the Phase Ib study.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-f0bf-7547-8ad6-12100ed22e83/13",
  "deckHref": "/decks/019de073-f0bf-7547-8ad6-12100ed22e83",
  "deckJsonHref": "/decks/019de073-f0bf-7547-8ad6-12100ed22e83.json",
  "deckAnchorHref": "/decks/019de073-f0bf-7547-8ad6-12100ed22e83#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.7,
        "x": 0.15,
        "y": 0.33
      },
      "kind": "chart",
      "text": "Mean Change from Baseline %BSA affected in treated areas",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c28a3e62-f9a4-46f4-b4f9-85b259a874ea",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.3,
        "x": 0.65,
        "y": 0.55
      },
      "kind": "legend",
      "text": "0.25% ointment, once per day, 10% BSA\n1% ointment, once per day, 10% BSA\n1% ointment, once per day, 30% BSA\n1% ointment, twice per day, 30% BSA\nPlacebo 7d\nPlacebo 14d",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "944f3754-b739-481a-b6c9-12c55cb2456f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "list",
      "text": "Phase Ib was NOT powered to meaningfully assess efficacy - only 6 patients dosed with active per group\nMaximum duration of dosing 14 days (EASI score changes typically measured at 28 days)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "31285897-0794-46fe-b49d-063d27a0488f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.05,
        "y": 0.13
      },
      "kind": "paragraph",
      "text": "Eczema Area and Severity Index (EASI)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c70b3f15-5e46-4fae-afe5-242e07710577",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.05,
        "y": 0.07
      },
      "kind": "title",
      "text": "BEN-2293 - indicative data from Phase Ib",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "51e525bb-bfbc-4c0f-9e50-9b061588311d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 17,
      "from": 9,
      "beatId": "992080ec-aa6d-4a45-852f-5530c22dd391",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 9-17 provide relief, highlighting the validation and potential of BenevolentAI's platform, as well as its business model and future prospects.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}